Faruqi and Faruqui, LLP Logo
Share this page

In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.)


In the Celebrex case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s blockbuster anti-inflammatory drug, Celebrex.  The case alleges that Pfizer procured a patent by committing Walker Process fraud and then filed patent litigation against generic drugmakers Teva Watson and Mylan, to delay their entry into the market with less-expensive generic versions of Celebrex , forcing direct purchasers to pay higher branded prices rather than lower generic prices for longer than they otherwise would have.  Celebrex had annual sales of over $1 billion during the relevant time, making the overcharge paid by direct purchasers quite substantial.

Contact Counsel

Peter Kohn
Joseph T. Lukens
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 09/13/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.